Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 353,983 shares of the biopharmaceutical company's stock, valued at approximately $2,966,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.69% of Emergent Biosolutions as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in EBS. Legal & General Group Plc acquired a new position in Emergent Biosolutions during the 2nd quarter worth about $31,000. Torren Management LLC bought a new stake in Emergent Biosolutions during the 4th quarter worth about $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions in the 4th quarter valued at about $45,000. Raymond James Financial Inc. bought a new position in shares of Emergent Biosolutions in the second quarter worth about $53,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 4,827 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.
Emergent Biosolutions Stock Down 0.3%
Shares of NYSE EBS opened at $5.92 on Friday. The firm has a market capitalization of $303.52 million, a PE ratio of -1.67 and a beta of 2.35. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. Emergent Biosolutions Inc. has a 1 year low of $4.36 and a 1 year high of $14.06. The firm's 50-day moving average is $6.88 and its 200-day moving average is $8.08.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.68. The business had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. Equities analysts expect that Emergent Biosolutions Inc. will post -4.61 EPS for the current year.
Insider Buying and Selling
In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.00% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Weiss Ratings raised shares of Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday, August 21st. Benchmark restated a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. started coverage on Emergent Biosolutions in a report on Friday, August 21st. They set an "underweight" rating on the stock. UBS Group reiterated a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, HC Wainwright lowered their target price on Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $10.00.
Get Our Latest Stock Analysis on EBS
About Emergent Biosolutions
(
Free Report)
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Emergent Biosolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.
While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
